Cariprazine: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Abstract
After completing this activity, participants should be able to: Differentiate cariprazine from aripiprazole and from higher-efficacy antipsychotics: identify the approval aripiprazole lacks (bipolar I depression, first-line in the 2023 CANMAT/ISBD update); place cariprazine in a 2026 network meta-analysis of 24 antipsychotics in acute schizophrenia. It was among the least sedating and among those with a smaller effect on overall symptoms, and it fell in the higher-risk group for akathisia with aripiprazole, while brexpiprazole was in the lower group; explain why its D3 preference remains a hypothesis for predominant negative symptoms, where the evidence is one sponsor-run 26-week trial against risperidone with no placebo arm (effect size 0.31). Apply cariprazine's dosing and interaction rules in practice: start at 1.5 mg once daily in every adult indication; in schizophrenia and mania, move to 3 mg on day 2 (maximum 6 mg); in bipolar depression and adjunctive MDD, move to 3 mg only from day 15 and only if needed (maximum 3 mg), with 1.5 mg preferred in bipolar depression; judge each dose over several weeks, and monitor for akathisia and extrapyramidal symptoms for several weeks after every change, because the active metabolite DDCAR (half-life 1 to 3 weeks) approaches steady state only at 4 to 8 weeks; under the US label, start at 0.5 mg with a strong and 0.75 mg with a moderate CYP3A4 inhibitor, and lower a stable dose when one is added; the EU, British and Canadian labels contraindicate strong inhibitors; avoid CYP3A4 inducers; manage akathisia by holding or stepping down the dose, allowing time for it to settle, or adding propranolol. Evaluate individual candidates by indication and patient profile: select cariprazine for bipolar I depression at 1.5 mg; select it for the patient whose weight gain, metabolic effects, hyperprolactinemia or sedation limited a previous antipsychotic, while counseling that long-term weight gain is larger (+2.5 kg at 48 weeks in open-label schizophrenia studies); weigh its place as an add-on in MDD: second-line in the 2023 CANMAT update, and ranked behind aripiprazole on both response and acceptability in a 2026 network meta-analysis; prefer an alternative: when akathisia already limits treatment; when sedation is the priority for an acutely agitated patient; when a CYP3A4 inducer cannot be stopped; when pregnancy is planned (DDCAR stays detectable up to 12 weeks after the last dose); for bipolar maintenance or bipolar II depression: the maintenance trial was inconclusive, and the one completed trial that enrolled bipolar II patients failed; when cost or formulary access is decisive (brand only in the US).